Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Ben Hendrix | RBC Capital Markets | 8 questions · 0% challenging |
| Ann Hynes | Mizuho Securities | 8 questions · 25% challenging |
| Andrew Mok | Barclays | 7 questions · 57% challenging |
| Matthew Gillmor | KeyBanc Capital Markets | 7 questions · 0% challenging |
| Ryan Langston | TD Cowen | 7 questions · 0% challenging |
| Steve Baxter | Wells Fargo | 6 questions · 50% challenging |
| Whit Mayo | Leerink Partners | 6 questions · 0% challenging |
| Scott Fidel | Goldman Sachs | 6 questions · 0% challenging |
| A.J. Rice | UBS | 6 questions · 0% challenging |
| Pito Chickering | Deutsche Bank | 6 questions · 50% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| RBC Capital Markets | 1 analyst | 8 questions · 0% challenging |
| Mizuho Securities | 1 analyst | 8 questions · 25% challenging |
| UBS | 2 analysts | 8 questions · 0% challenging |
| Goldman Sachs | 2 analysts | 7 questions · 0% challenging |
| KeyBanc Capital Markets | 1 analyst | 7 questions · 0% challenging |
| Leerink Partners | 2 analysts | 7 questions · 0% challenging |
| Jefferies | 2 analysts | 7 questions · 0% challenging |
| Barclays | 1 analyst | 7 questions · 57% challenging |
Reporting soon: earnings call Tuesday, Oct 27
A pre-earnings brief is ready for HCA: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
No 8-K events recorded for this window.
HCA Healthcare opened FY2026 with revenue up 4.3% year-over-year and adjusted diluted EPS up approximately 11%, while adjusted EBITDA grew almost 2% as an unusually mild respiratory season and a January winter storm together cut an estimated $180 million from EBITDA. The volume miss was concentrated in January (same-facility admissions rose 0.9% and ER visits 0.3%), but management said February and March rebounded toward the full-year 2% to 3% growth plan. A larger-than-expected net benefit of roughly $200 million from Medicaid supplemental payment programs (Georgia, the reinstated Texas Atlas program and Tennessee) largely offset the seasonal drag, even as the health-insurance-exchange shift cut exchange equivalent admissions about 15% for an estimated $150 million EBITDA impact in the quarter. Management reaffirmed full-year 2026 guidance, framing the first-quarter headwinds as temporal rather than structural and holding the $600 million to $900 million exchange-impact range and $400 million resiliency target unchanged.
Calendar quarter Q1 2026Earnings call Apr 24, 2026
FY2026 Q1 in brief
HCA Healthcare opened FY2026 with revenue up 4.3% year-over-year and adjusted diluted EPS up approximately 11%, while adjusted EBITDA grew almost 2% as an unusually mild respiratory season and a January winter storm together cut an estimated $180 million…
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for HCA Healthcare (HCA), FY2026 Q1: 6/10. Scores: HCA Healthcare’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: HCA daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Net margin | FCF |
|---|---|---|---|---|---|---|
| FY2024 Q4 | $18.29B | +5.7% | $5.63 | -5.1% | 7.9% | $1.27B |
| FY2025 Q1 | $18.32B | +5.7% | $6.45 | +8.8% | 8.8% | $660M |
| FY2025 Q2 | $18.61B | +6.4% | $6.83 | +23.5% | 8.9% | $3.03B |
| FY2025 Q3 | $19.16B | +9.6% | $6.96 | +42.6% | 8.6% | $3.13B |
| FY2025 Q4 | $19.51B | +6.7% | $8.14 | +44.6% | 9.6% | $870M |
| FY2026 Q1Selected | $19.11B | +4.3% | $7.15 | +10.9% | 8.5% | $895M |
| FY2026 Q2 | $20.23B | +8.7% | $7.62 | +11.6% | 8.4% | $1.10B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Demand | Regulation Policy | Cost Pressure | Revenue Growth | Guidance Reliability | Competitive Dynamics | Pricing | Labor Market | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 5 | 5 | 4 | 1 | 2 | 1 | 3 |
| 2025Q1 | 6 | 4 | 2 | 1 | 3 | 2 | 4 | 2 |
| 2025Q2 | 6 | 5 | 4 | 2 | 3 | 3 | 1 | |
| 2025Q3 | 5 | 4 | 4 | 3 | 3 | 2 | 2 | 1 |
| 2025Q4 | 4 | 6 | 3 | 2 | 3 | 2 | 1 | |
| 2026Q1 | 10 | 6 | 2 | 7 | 5 | 2 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 6 | 6 | 5 | 4 | 10 |
| Regulation Policy | 5 | 4 | 5 | 4 | 6 | 6 |
| Cost Pressure | 5 | 2 | 4 | 4 | 3 | 2 |
| Revenue Growth | 4 | 1 | 3 | 2 | 7 | |
| Guidance Reliability | 1 | 3 | 2 | 3 | 3 | 5 |
| Competitive Dynamics | 2 | 2 | 3 | 2 | 2 | 2 |
| Pricing | 1 | 4 | 3 | 2 | 1 | 1 |
| Labor Market | 3 | 2 | 1 | 1 | 1 |
GAAP revenue YoY +4.30% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
What HCA said about other companies on its FY2026 Q1 call, and what other companies said about HCA on their calls covering the same calendar quarter (Q1 2026). Each company's own fiscal quarter is shown next to its name. Extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“several large renewals with leading health system partners, including Baylor Scott & White, Norton Health and HCA.”
HCA is named among the leading health-system tenants that signed large outpatient-medical lease renewals with Healthpeak this quarter.
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| HCAHCA Healthcare | 6 | +4.3% | HCA Healthcare opened FY2026 with revenue up 4.3% year-over-year and adjusted diluted EPS up approximately 11%, while adjusted EBITDA grew almost 2% as an unusually mild respiratory season and a January winter storm together cut an estimated $180 million from EBITDA | |
| DVADaVita | 7 | +6.0% | Guidance Raised on Volume and Cost Outperformance | |
| UHSUniversal Health Services | 7 | +9.7% | Talkspace Acquisition Accelerates Outpatient Behavioral Continuum |
HCA Healthcare opened FY2026 with revenue up 4.3% year-over-year and adjusted diluted EPS up approximately 11%, while adjusted EBITDA grew almost 2% as an unusually mild respiratory season and a January winter storm together cut an estimated $180 million from EBITDA
Talkspace Acquisition Accelerates Outpatient Behavioral Continuum
| Company | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|---|
| HCA | 6 | 7 | 8 | 9 | 7 | 6 |
| DVA | 8 | 5 | 6 | 5 | 7 | 7 |
| UHS | 9 | 7 | 9 | 9 | 8 | 7 |